DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it would report its financial results for the fourth quarter and full year of 2010 on Monday, March 7, 2011 at the opening of the financial markets. The announcement will be followed by a conference call with the investment community scheduled for the same day in the afternoon at 4:30 PM ET.
Neoprobe’s President and CEO, David Bupp, Executive Vice President and CDO, Dr. Mark Pykett, Senior Vice President, Pharmaceutical Research and Clinical Development, Dr. Fred Cope, and Senior Vice President and CFO, Brent Larson, will provide a development and business update and will discuss the Company’s financial results for the fourth quarter and full year of 2010 during the conference call. The conference call can be accessed as follows:
| Conference Call Information | ||||||
| TO PARTICIPATE LIVE: | TO LISTEN TO A REPLAY: | |||||
| Date: |
Mar. 7, 2011 |
Available until: |
Mar. 21, 2011 |
|||
| Time: | 4:30 PM ET | Toll-free (U.S.) Dial in # : | (877) 660-6853 | |||
| International Dial in # : | (201) 612-7415 | |||||
| Toll-free (U.S.) Dial in # : | (877) 407-8033 | |||||
| International Dial in # : | (201) 689-8033 | Replay passcode: | ||||
| Account #: | 286 | |||||
| Conference ID #: | 368667 | |||||
About Neoprobe
Neoprobe is a biomedical company focused on enhancing oncology patient care and improving patient benefit. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScanTM CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com